SEC INSIDER TRANSACTIONS

QUEST DIAGNOSTICS INC (DGX) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

DGX · QUEST DIAGNOSTICS INC

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 39 filings · fetched 2026-11-13T17:19:48Z

Recent reported activity

0purchase rows on this page

11sale rows on this page

63matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-11-09Filed 2026-11-12	Plewman PatrickOfficer · SVP for Diagnostic Services Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. References: F1, F3	M Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative	6,793D	127.805	Direct	Form 4 ↗0001022079-26-000125
2026-11-09Filed 2026-11-12	Plewman PatrickOfficer · SVP for Diagnostic Services Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. References: F1, F3	M Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative	4,274D	127.725	Direct	Form 4 ↗0001022079-26-000125
2026-11-09Filed 2026-11-12	Plewman PatrickOfficer · SVP for Diagnostic Services Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. References: F2	S Sale (market/private)Common Stock · Non-derivative	650D	257.34	Direct	Form 4 ↗0001022079-26-000125
2026-11-09Filed 2026-11-12	Plewman PatrickOfficer · SVP for Diagnostic Services Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. References: F1	S Sale (market/private)Common Stock · Non-derivative	6,793D	257.34	Direct	Form 4 ↗0001022079-26-000125
2026-11-09Filed 2026-11-12	Plewman PatrickOfficer · SVP for Diagnostic Services Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. References: F1	M Exercise / conversionCommon Stock · Non-derivative	6,793A	127.805	Direct	Form 4 ↗0001022079-26-000125
2026-11-09Filed 2026-11-12	Plewman PatrickOfficer · SVP for Diagnostic Services Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. References: F1	S Sale (market/private)Common Stock · Non-derivative	4,274D	257.34	Direct	Form 4 ↗0001022079-26-000125
2026-11-09Filed 2026-11-12	Plewman PatrickOfficer · SVP for Diagnostic Services Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. References: F1	M Exercise / conversionCommon Stock · Non-derivative	4,274A	127.725	Direct	Form 4 ↗0001022079-26-000125
2026-11-03Filed 2026-11-05	DELANEY MARK EOfficer · SVP & Chief Commercial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents an award of restricted stock units. References: F1	A Award / grantCommon Stock · Non-derivative	2,615A	0	Direct	Form 4 ↗0001022079-26-000121
2026-11-03Filed 2026-11-05	Doherty Catherine T.Officer · Executive Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents an award of restricted stock units. F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 This transaction was executed in multiple trades at prices ranging from $244.840 to $245.8353. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $245.845 to $246.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 This transaction was executed in multiple trades at prices ranging from $246.850 to $247.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 This transaction was executed in multiple trades at prices ranging from $247.930 to $248.7825. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 This transaction was executed in multiple trades at prices ranging from $249.005 to $250.0008. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 This transaction was executed in multiple trades at prices ranging from $250.005 to $251.0036. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 This transaction was executed in multiple trades at prices ranging from $251.005 to $251.700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F11 The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024. References: F2, F11	M Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative	22,105D	121.805	Direct	Form 4 ↗0001022079-26-000122
2026-11-03Filed 2026-11-05	Doherty Catherine T.Officer · Executive Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents an award of restricted stock units. F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 This transaction was executed in multiple trades at prices ranging from $244.840 to $245.8353. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $245.845 to $246.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 This transaction was executed in multiple trades at prices ranging from $246.850 to $247.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 This transaction was executed in multiple trades at prices ranging from $247.930 to $248.7825. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 This transaction was executed in multiple trades at prices ranging from $249.005 to $250.0008. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 This transaction was executed in multiple trades at prices ranging from $250.005 to $251.0036. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 This transaction was executed in multiple trades at prices ranging from $251.005 to $251.700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F11 The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024. References: F2, F9	S Sale (market/private)Common Stock · Non-derivative	2,907D	251.2386	Direct	Form 4 ↗0001022079-26-000122
2026-11-03Filed 2026-11-05	Doherty Catherine T.Officer · Executive Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents an award of restricted stock units. F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 This transaction was executed in multiple trades at prices ranging from $244.840 to $245.8353. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $245.845 to $246.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 This transaction was executed in multiple trades at prices ranging from $246.850 to $247.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 This transaction was executed in multiple trades at prices ranging from $247.930 to $248.7825. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 This transaction was executed in multiple trades at prices ranging from $249.005 to $250.0008. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 This transaction was executed in multiple trades at prices ranging from $250.005 to $251.0036. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 This transaction was executed in multiple trades at prices ranging from $251.005 to $251.700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F11 The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024. References: F2, F8	S Sale (market/private)Common Stock · Non-derivative	2,877D	250.4882	Direct	Form 4 ↗0001022079-26-000122
2026-11-03Filed 2026-11-05	Doherty Catherine T.Officer · Executive Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents an award of restricted stock units. F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 This transaction was executed in multiple trades at prices ranging from $244.840 to $245.8353. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $245.845 to $246.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 This transaction was executed in multiple trades at prices ranging from $246.850 to $247.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 This transaction was executed in multiple trades at prices ranging from $247.930 to $248.7825. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 This transaction was executed in multiple trades at prices ranging from $249.005 to $250.0008. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 This transaction was executed in multiple trades at prices ranging from $250.005 to $251.0036. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 This transaction was executed in multiple trades at prices ranging from $251.005 to $251.700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F11 The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024. References: F2, F7	S Sale (market/private)Common Stock · Non-derivative	3,004D	249.4035	Direct	Form 4 ↗0001022079-26-000122
2026-11-03Filed 2026-11-05	Doherty Catherine T.Officer · Executive Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents an award of restricted stock units. F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 This transaction was executed in multiple trades at prices ranging from $244.840 to $245.8353. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $245.845 to $246.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 This transaction was executed in multiple trades at prices ranging from $246.850 to $247.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 This transaction was executed in multiple trades at prices ranging from $247.930 to $248.7825. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 This transaction was executed in multiple trades at prices ranging from $249.005 to $250.0008. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 This transaction was executed in multiple trades at prices ranging from $250.005 to $251.0036. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 This transaction was executed in multiple trades at prices ranging from $251.005 to $251.700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F11 The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024. References: F2, F6	S Sale (market/private)Common Stock · Non-derivative	2,358D	248.3838	Direct	Form 4 ↗0001022079-26-000122
2026-11-03Filed 2026-11-05	Doherty Catherine T.Officer · Executive Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents an award of restricted stock units. F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 This transaction was executed in multiple trades at prices ranging from $244.840 to $245.8353. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $245.845 to $246.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 This transaction was executed in multiple trades at prices ranging from $246.850 to $247.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 This transaction was executed in multiple trades at prices ranging from $247.930 to $248.7825. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 This transaction was executed in multiple trades at prices ranging from $249.005 to $250.0008. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 This transaction was executed in multiple trades at prices ranging from $250.005 to $251.0036. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 This transaction was executed in multiple trades at prices ranging from $251.005 to $251.700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F11 The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024. References: F2, F5	S Sale (market/private)Common Stock · Non-derivative	1,151D	246.9835	Direct	Form 4 ↗0001022079-26-000122
2026-11-03Filed 2026-11-05	Doherty Catherine T.Officer · Executive Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents an award of restricted stock units. F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 This transaction was executed in multiple trades at prices ranging from $244.840 to $245.8353. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $245.845 to $246.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 This transaction was executed in multiple trades at prices ranging from $246.850 to $247.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 This transaction was executed in multiple trades at prices ranging from $247.930 to $248.7825. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 This transaction was executed in multiple trades at prices ranging from $249.005 to $250.0008. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 This transaction was executed in multiple trades at prices ranging from $250.005 to $251.0036. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 This transaction was executed in multiple trades at prices ranging from $251.005 to $251.700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F11 The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024. References: F2, F4	S Sale (market/private)Common Stock · Non-derivative	5,990D	246.2649	Direct	Form 4 ↗0001022079-26-000122
2026-11-03Filed 2026-11-05	Doherty Catherine T.Officer · Executive Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents an award of restricted stock units. F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 This transaction was executed in multiple trades at prices ranging from $244.840 to $245.8353. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $245.845 to $246.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 This transaction was executed in multiple trades at prices ranging from $246.850 to $247.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 This transaction was executed in multiple trades at prices ranging from $247.930 to $248.7825. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 This transaction was executed in multiple trades at prices ranging from $249.005 to $250.0008. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 This transaction was executed in multiple trades at prices ranging from $250.005 to $251.0036. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 This transaction was executed in multiple trades at prices ranging from $251.005 to $251.700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F11 The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024. References: F2, F3	S Sale (market/private)Common Stock · Non-derivative	3,818D	245.4519	Direct	Form 4 ↗0001022079-26-000122
2026-11-03Filed 2026-11-05	Doherty Catherine T.Officer · Executive Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents an award of restricted stock units. F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 This transaction was executed in multiple trades at prices ranging from $244.840 to $245.8353. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $245.845 to $246.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 This transaction was executed in multiple trades at prices ranging from $246.850 to $247.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 This transaction was executed in multiple trades at prices ranging from $247.930 to $248.7825. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 This transaction was executed in multiple trades at prices ranging from $249.005 to $250.0008. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 This transaction was executed in multiple trades at prices ranging from $250.005 to $251.0036. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 This transaction was executed in multiple trades at prices ranging from $251.005 to $251.700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F11 The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024. References: F2	M Exercise / conversionCommon Stock · Non-derivative	22,105A	121.805	Direct	Form 4 ↗0001022079-26-000122
2026-11-03Filed 2026-11-05	Doherty Catherine T.Officer · Executive Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents an award of restricted stock units. F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3 This transaction was executed in multiple trades at prices ranging from $244.840 to $245.8353. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $245.845 to $246.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 This transaction was executed in multiple trades at prices ranging from $246.850 to $247.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 This transaction was executed in multiple trades at prices ranging from $247.930 to $248.7825. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 This transaction was executed in multiple trades at prices ranging from $249.005 to $250.0008. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 This transaction was executed in multiple trades at prices ranging from $250.005 to $251.0036. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 This transaction was executed in multiple trades at prices ranging from $251.005 to $251.700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F11 The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024. References: F1	A Award / grantCommon Stock · Non-derivative	4,827A	0	Direct	Form 4 ↗0001022079-26-000122
2026-11-03Filed 2026-11-05	Ramachandran SubuOfficer · SVP, Regional Businesses Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents an award of restricted share units. F2 The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. References: F2	A Award / grantNon-Qualifed Stock Option (right to buy) · Derivative	1,386A	0	Direct	Form 4 ↗0001022079-26-000123
2026-11-03Filed 2026-11-05	Ramachandran SubuOfficer · SVP, Regional Businesses Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents an award of restricted share units. F2 The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. References: F1	A Award / grantCommon Stock · Non-derivative	352A	0	Direct	Form 4 ↗0001022079-26-000123
2026-10-26Filed 2026-10-28	PFEIFFER GARY MDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. References: F1	S Sale (market/private)Common Stock · Non-derivative	1,203D	243	Direct	Form 4 ↗0001022079-26-000118
2026-10-21Filed 2026-10-23	DELANEY MARK EOfficer · SVP & Chief Commercial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. References: F1	L Other reported codeCommon Stock · Non-derivative	25A	235.941	Direct	Form 4 ↗0001022079-26-000109
2026-10-21Filed 2026-10-23	MAIN TIMOTHY LDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. References: F1	L Other reported codeCommon Stock · Non-derivative	18A	235.937	Direct	Form 4 ↗0001022079-26-000110
2026-10-21Filed 2026-10-23	Plewman PatrickOfficer · SVP for Diagnostic Services Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. References: F1	L Other reported codeCommon Stock · Non-derivative	41A	235.94	Direct	Form 4 ↗0001022079-26-000111
2026-10-21Filed 2026-10-23	Lassiter Wright IIIDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. References: F1	L Other reported codeCommon Stock · Non-derivative	6A	235.959	Direct	Form 4 ↗0001022079-26-000112

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.